Abstract
The increasing incidence of a variety of infections due to Staphylococcus aureus and the expanding role of community-associated methicillin-resistant S. aureus has led to an emphasis on the need for safe and effective agents to treat both systemic and localized Staphylococcal infections. Several newer antimicrobial agents are available for treatment of systemic Staphylococcal infections, but their use may be limited by the relatively high cost of these agents or the need forparenteral administration. Clindamycin has been used successfully to treat soft-tissue and musculoskeletal infections due to MRSA, in adults and children. However, concern over the possibility of the emergence of clindamycin resistance during therapy has discouraged some clinicians from prescribing that agent. Simple laboratory testing (e.g., the erythromycin-clindamycin 'D-zone' test) can separate strains that have the genetic potential (i.e., the presence of erm genes) to become resistant during therapy, from strains that are fully susceptible to clindamycin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
